Primary Cells Market
Global Industry Analysis and Forecast 2023-2030
Market Value (2022)
USD 1.23 Billion
Forecasted Value (2030)
USD 2.88 Billion
CAGR (2023 - 2030)
Fastest Growing Region (2023 - 2030)
Hematopoietic Cells, Skin Cells, Liver Cells, Renal Cells, Skeletal and Muscle Cells, Others
Human Primary Cells, Animal Primary Cells
Pharmaceutical & Biotechnology Companies, Research Institutes
The global Primary Cells Market was valued at USD 1.23 billion in 2022 and is projected to reach USD 2.88 billion by 2030, growing at a CAGR of 11.41% from 2023 to 2030.
Primary cell cultures are becoming increasingly popular for in vitro testing and drug screening due to their significance in in-vivo settings. These cultures are created by extracting living tissues and propagating them in vitro while preserving their genetic and phenotypic characteristics. Moreover, the increasing use of primary cell cultures for in vitro testing and drug screening is due to their accuracy, specificity, reproducibility, and technological advances in their production and maintenance. Primary cell cultures are increasingly popular for drug development and personalized medicine, and their demand is expected to increase further as technology advances. However, the market faces several challenges, which include variability in growth rates, difficulty maintaining viability, and heterogeneity between cells. Fluctuations in growth rates can lead to inconsistent test results and difficulties in data management and interpretation. Primary cells also have a limited lifespan outside their natural environment, which can cause problems maintaining their viability over a long period of time.
Analyst’s Review on Primary Cells Market
Advances in technology have also contributed to the increased use of primary cell cultures. Technological advancement has made it easier and more cost-effective to produce and maintain high-quality primary cell cultures. These advancements have helped improve the accuracy and reproducibility of primary cell cultures in drug development and personalized medicine. Additionally, a more individualized assessment of the toxicity and efficacy of medication candidates can be made with the utilization of primary cell cultures from various organs and physiological states.
Primary cells can be used to screen potential drug candidates for toxicity and efficacy, reducing the need for animal testing and improving the accuracy of initial drug screening. These cells have begun to emerge as an essential tool in cell and molecular biology research, offering high-quality contextual models of healthy cell physiology and signaling, illness, and therapeutic agents. They have significance in cancer biology and the screening of prospective anticancer medicines. Primary cell cultures preserve the genetic and phenotypic characteristics of the cells in vivo and are therefore more relevant for analyzing drug response and toxicity.
Primary cell cultures are an essential tool for in vitro testing and drug screening. In vitro, development of primary cells is an emerging field for regenerative medicine and the regeneration of damaged tissues and/or body organs. Recent advancements in cell culture technology and three-dimensional (3D) cell models have made primary cells an increasingly valuable resource for drug discovery, toxicity testing, and disease modeling.
Concern about contamination of primary cell cultures is a major factor that can affect the market share. Contamination can lead to inaccurate test results, which delays R&D activities and undermines confidence in the reliability of primary cell culture studies. Contamination can also increase the cost of primary cell culture production, as it requires additional time and resources to identify and repair contaminated cultures. This may ultimately lead to reduced demand for primary cells, which may restrict market growth. Researchers continue to develop and optimize methods to produce and maintain high-quality primary cell cultures to address these issues and advance scientific understanding.
The global primary cells market is segmented based on origin, type, end-user, and geography.
Based on origin, the market is classified into hematopoietic cells, skin cells, liver cells, renal cells, skeletal and muscle cells, and others. The hematopoietic cells segment held the largest market share of 28.10% in 2022. This is due to an increase in blood cancer cases and a rise in stem cell research projects. These cells are used to understand the biochemical pathways of tumor cells and the effectiveness of various drugs.
Based on type, the primary cells market is segmented into human primary cells and animal primary cells. The human primary cells segment dominated market growth in 2022 with a market share of 57.02%. The expanding use of primary human cells in the creation of innovative cancer medicines and the rising funding for cell therapy R&D activities propel the segment's share.
Based on end-user, the primary cells market is classified into pharmaceutical & biotechnology companies and research institutes. Pharmaceutical and biotechnology firms dominated the market share primarily because the products they provide are used to manufacture medicines. Primary cells are in high demand as an alternative to animal models for testing new medications and chemicals.
Based on regional analysis, the global primary cells market is classified into North America, Europe, Asia Pacific, MEA, and Latin America.
The primary cell market in North America is the dominant region, with a market share of 40.52% in 2022. Increased interest in the construction of 3D models and the use of advanced technologies such as gene editing and organ-on-a-chip technology to improve the accuracy and efficiency of primary cell research drives the market growth. Researchers are also increasingly focused on developing tailored treatments for cancer and other diseases using primary cells, and there has been growing interest in using primary cells to develop cell-based therapies for spinal cord injuries and heart disease. Moreover, recent trends in the use of primary cells in North America indicate the continued development and application of advanced techniques in primary cell research and an increased focus on the progress of personalized and targeted disease therapies.
The primary cell market in Europe held the second-dominating position, with a market share of 33.34% in 2022. These cells are widely used in scientific research and the development of potential treatments for various diseases, including cancer. In Europe, there are many companies and research institutes specializing in the production and use of primary cells. European research institutes and organizations such as the European Bank for Induced Pluripotent Stem Cells (EBiSC) and the European Authenticated Cell Culture Collection (ECACC) provide essential resources for researchers of primary cells. Additionally, researchers across the region are increasingly interested in creating 3D models of cancer using primary cells, which allows more accurate modeling of the complex interactions between cancer cells and their surrounding microenvironment. Drug development has also increased across the region, with the aim of developing more effective and targeted cancer treatments. Moreover, recent trends in the usage of primary cells in Europe reflect a growing interest in employing these cells to produce personalized and focused medicines for cancer and other disorders and a growing emphasis on cell regeneration technologies.
The global primary cells industry study report will provide valuable insight with an emphasis on the fragmented nature of the global market. Prominent players are focusing on several key business strategies such as partnerships, mergers and acquisitions, product innovations, and joint ventures to expand their product portfolio and increase their respective market shares across different regions. Development and investments involve a range of strategic initiatives including investments in R&D activities, new manufacturing facilities, and supply chain optimization.
The major players in the primary cells market are
- AnaBios Corporation
- Cell Biologics, Inc.
- Corning Incorporated
- Lonza Group Ltd.
- Merck KGaA
- PBS Biotech Inc
- PromoCell GmbH
- Thermo Fisher Scientific, Inc.
- ZenBio, Inc.
- STEMCELL Technologies
- April 2023 (Acquisition): AnaBios Corporation acquired Cell Systems, which further enhances AnaBios' unique portfolio of human tissues and cells, helping researchers accelerate drug discovery and advance their understanding of cell biology using a wide range of biologically relevant tools.
- April 2020 (Product Launch): StemBioSys launched CELLvo human articular chondrocytes, low-range cells for highly relevant cartilage research. CELLvo Chondrocytes have been shown to minimize phenotype loss during in vitro expansion on CELLvo Matrix by expressing a high ratio of collagen type 2 (Col2) to collagen type 1 (Col1).
The global Primary Cells Market is segmented as:
- Hematopoietic Cells
- Skin Cells
- Liver Cells
- Renal Cells
- Skeletal and Muscle Cells
- Human Primary Cells
- Animal Primary Cells
- Pharmaceutical & Biotechnology Companies
- Research Institutes
- North America
- Rest of Europe
- Asia Pacific
- South Korea
- Rest of Asia Pacific
- Middle East & Africa
- North Africa
- South Africa
- Rest of the Middle East & Africa
- Latin America
- Rest of Latin America